粒细胞-巨噬细胞集落刺激因子(GM-CSF)作为银屑病治疗靶点:使用特异性人抗GM-CSF单克隆抗体纳米鲁单抗的随机对照研究
这项II期多中心随机双盲安慰剂对照平行组剂量探索概念验证研究(NEPTUNE)比较了四种剂量纳米鲁单抗(20、50、80、150 mg皮下注射)与安慰剂在中重度斑块状银屑病患者中的疗效与安全性,主要终点为第12周PASI 75应答率。共入组122例患者,106例(86.9%)完成双盲治疗,16例(13.1%)提前终止研究药物。第12周PASI 75应答人数在所有组中均较低,安慰剂与任一纳米鲁单抗组间该终点均无显著差异,其他临床终点结果相似,炎症通路相关细胞类型、亚群及细胞因子的实验室检查亦未见显著治疗相关变化。结论认为GM-CSF阻断对抑制银屑病关键炎症通路并非关键。
要点
- 第12周PASI 75应答人数在所有组中均较低,安慰剂与任一纳米鲁单抗组间无显著差异。
- 其他临床研究终点结果与主要终点相似,未见显著差异。
- 炎症通路相关细胞类型、亚群及细胞因子的实验室检查未见显著治疗相关变化。
核心结论
- GM-CSF阻断对抑制银屑病关键炎症通路并非关键。
研究设计与样本
- II期、多中心、随机、双盲、安慰剂对照、平行组、剂量探索、概念验证研究(NEPTUNE),比较四种剂量纳米鲁单抗(20、50、80、150 mg皮下注射)与安慰剂。
- 共入组122例中重度斑块状银屑病患者,106例(86.9%)完成双盲治疗,16例(13.1%)提前终止研究药物。
- 主要终点为第12周达到PASI 75治疗应答(PASI较基线降低≥75%)的患者比例,并在总体研究人群的一个亚组中进行组织水平的探索性研究。
- 试验注册号为NCT02129777。
主要发现
- 皮下给予IgG1单克隆抗体的血清浓度-时间曲线符合预期,暴露量随剂量升高成比例增加。
- 第12周PASI 75应答人数在所有组中均较低,安慰剂与任一纳米鲁单抗组间该终点均无显著差异。
- 其他临床研究终点结果相似,未见显著差异。
- 炎症通路相关细胞类型、亚群及细胞因子的实验室检查未见显著治疗相关变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relevance of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of psoriasis has not been studied previously. GM-CSF is important in the initiation and maintenance of chronic inflammatory processes. OBJECTIVES: To investigate the clinical use of GM-CSF neutralization by evaluating the efficacy and safety of namilumab (AMG203), a monoclonal antibody GM-CSF inhibitor, in patients with moderate-to-severe plaque psoriasis. METHODS: A phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group, dose-finding, proof-of-concept study (NEPTUNE) was conducted. Four doses of namilumab (20, 50, 80 and 150 mg, via subcutaneous injection) were compared with placebo. Assessment of the primary end point - the proportion of patients achieving ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75 treatment response) - was performed at week 12. Exploratory investigation at the tissue level was conducted in a subset of the overall study population. The trial was registered with the number NCT02129777. RESULTS: In total, 122 patients were enrolled and 106 (86·9%) completed the double-blind treatment; 16 (13·1%) prematurely discontinued study medication. Serum concentration-time profiles were as expected for subcutaneous delivery of an IgG1 monoclonal antibody, and exposure increased proportionally with dose elevation. The number of patients showing PASI 75 treatment response at week 12 was low in all groups; no significant difference was recorded in this end point between placebo and any namilumab group. Similar outcomes were recorded for other clinical study end points. Moreover, no significant treatment-related changes from baseline were observed in laboratory investigations of cell types or subpopulations, or cytokines relevant to inflammatory pathways in psoriasis. CONCLUSIONS: GM-CSF blockade is not critical for suppression of key inflammatory pathways underlying psoriasis.
引用
- Papp KA, Gooderham M, Jenkins R, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. Br J Dermatol. 2018. PMID: 30207587. doi:10.1111/bjd.17195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。